After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Clearing 19 biologics for Europe market
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
The company reported consolidated revenue of Rs. 172.9 crore and EBITDA of Rs 25.9 crore in FY26
As per union government, growing public participation reflects rising awareness and collective commitment towards advancing organ and tissue donation
Advanced comprehensive oncology centre was inaugurated by the legendary former Indian cricketer VVS Laxman
Social media emerges as the primary channel for health-related scams, while influencer endorsements and AI-generated content amplify risks for consumers
The company said the safety profile remained consistent with earlier studies and was considered manageable
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
